457 related articles for article (PubMed ID: 29266694)
1. Clinical and economic impact of school-based nonavalent human papillomavirus vaccine on women in Singapore: a transmission dynamic mathematical model analysis.
Tay SK; Hsu TY; Pavelyev A; Walia A; Kulkarni AS
BJOG; 2018 Mar; 125(4):478-486. PubMed ID: 29266694
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of the nonavalent human papillomavirus vaccine for the prevention of cervical cancer in Singapore.
Phua LC; Choi HCW; Wu J; Jit M; Low J; Ng K; Pearce F; Hall C; Abdul Aziz MI
Vaccine; 2021 Apr; 39(16):2255-2263. PubMed ID: 33744050
[TBL] [Abstract][Full Text] [Related]
3. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of different human papillomavirus vaccines in Singapore.
Lee VJ; Tay SK; Teoh YL; Tok MY
BMC Public Health; 2011 Mar; 11():203. PubMed ID: 21453537
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
6. Estimating the epidemiological impact and cost-effectiveness profile of a nonavalent HPV vaccine in Spain.
De La Fuente J; Hernandez Aguado JJ; San Martín M; Ramirez Boix P; Cedillo Gómez S; López N
Hum Vaccin Immunother; 2019; 15(7-8):1949-1961. PubMed ID: 30698488
[TBL] [Abstract][Full Text] [Related]
7. The cost effectiveness of a quadrivalent human papillomavirus vaccine (6/11/16/18) in Hungary.
Dasbach EJ; Nagy L; Brandtmüller A; Elbasha EH
J Med Econ; 2010 Mar; 13(1):110-8. PubMed ID: 20085477
[TBL] [Abstract][Full Text] [Related]
8. Estimating the cost-effectiveness profile of a universal vaccination programme with a nine-valent HPV vaccine in Austria.
Boiron L; Joura E; Largeron N; Prager B; Uhart M
BMC Infect Dis; 2016 Apr; 16():153. PubMed ID: 27084683
[TBL] [Abstract][Full Text] [Related]
9. The Clinical and Economic Impact of a Nonavalent Versus Bivalent Human Papillomavirus National Vaccination Program in Taiwan.
Chou HH; Chang SC; Sukarom I; Saxena K; Pavelyev A; Wu YH; Chang CJ
Value Health Reg Issues; 2022 Nov; 32():79-87. PubMed ID: 36116338
[TBL] [Abstract][Full Text] [Related]
10. Public health impact and cost effectiveness of routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan: a model-based study.
Cody P; Tobe K; Abe M; Elbasha EH
BMC Infect Dis; 2021 Jan; 21(1):11. PubMed ID: 33407188
[TBL] [Abstract][Full Text] [Related]
11. Potential cost-effectiveness of the nonavalent human papillomavirus (HPV) vaccine.
Drolet M; Laprise JF; Boily MC; Franco EL; Brisson M
Int J Cancer; 2014 May; 134(9):2264-8. PubMed ID: 24174175
[TBL] [Abstract][Full Text] [Related]
12. Cost-Effectiveness of Bivalent, Quadrivalent, and Nonavalent HPV Vaccination in South Africa.
Michaeli DT; Stoycheva S; Marcus SM; Zhang W; Michaeli JC; Michaeli T
Clin Drug Investig; 2022 Apr; 42(4):333-343. PubMed ID: 35294726
[TBL] [Abstract][Full Text] [Related]
13. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of the introduction of two-dose bi-valent (Cervarix) and quadrivalent (Gardasil) HPV vaccination for adolescent girls in Bangladesh.
Mahumud RA; Gow J; Alam K; Keramat SA; Hossain MG; Sultana M; Sarker AR; Islam SMS
Vaccine; 2020 Jan; 38(2):165-172. PubMed ID: 31668820
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of two-dose human papillomavirus vaccination in Singapore.
Tay SK; Lee BW; Sohn WY; Lee IH; Mathur G; Sanicas M; Van Kriekinge G
Singapore Med J; 2018 Jul; 59(7):370-382. PubMed ID: 28983579
[TBL] [Abstract][Full Text] [Related]
16. Impact of including boys in the national school-based human papillomavirus vaccination programme in Singapore: A modelling-based cost-effectiveness analysis.
Wahab MT; Tan RKJ; Cook AR; Prem K
Vaccine; 2023 Mar; 41(12):1934-1942. PubMed ID: 36797100
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland.
Szucs TD; Largeron N; Dedes KJ; Rafia R; Bénard S
Curr Med Res Opin; 2008 May; 24(5):1473-83. PubMed ID: 18413014
[TBL] [Abstract][Full Text] [Related]
18. Inclusion of the benefits of enhanced cross-protection against cervical cancer and prevention of genital warts in the cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
Westra TA; Stirbu-Wagner I; Dorsman S; Tutuhatunewa ED; de Vrij EL; Nijman HW; Daemen T; Wilschut JC; Postma MJ
BMC Infect Dis; 2013 Feb; 13():75. PubMed ID: 23390964
[TBL] [Abstract][Full Text] [Related]
19. Prophylaxis of cervical cancer and related cervical disease: a review of the cost-effectiveness of vaccination against oncogenic HPV types.
Armstrong EP
J Manag Care Pharm; 2010 Apr; 16(3):217-30. PubMed ID: 20331326
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]